Evaluation of Nasal Bleeding in a Patient on Apixaban
In addition to CBC, you must check renal function (creatinine/CrCl), liver function tests, and consider coagulation studies including PT/INR and aPTT to assess bleeding severity and guide management decisions. 1
Essential Laboratory Workup
Renal Function Assessment
- Creatinine clearance (CrCl) is critical because apixaban's half-life varies dramatically with renal function—from 6-15 hours with normal function to 17 hours with CrCl <15 mL/min 1
- This directly impacts drug accumulation and bleeding risk
- Determines timing for drug clearance if anticoagulation needs to be held
Liver Function Tests
- Apixaban is metabolized hepatically
- Hepatic impairment increases bleeding risk and affects drug clearance 2
- Essential for determining if dose adjustment or drug discontinuation is needed
Coagulation Studies
While DOACs don't require routine monitoring, in the setting of active bleeding, specific testing helps determine:
- Anti-Factor Xa activity (if available): Most accurate for quantifying apixaban levels, though not standardized across institutions 3, 4
- PT/INR and aPTT: These provide qualitative assessment—PT may be mildly prolonged with apixaban, though not reliably 4
- Baseline coagulation parameters help identify concurrent coagulopathy
Additional Considerations
For epistaxis specifically:
- Coagulation screening is particularly useful in anticoagulated patients with epistaxis 5, 6
- One study found 16% of anticoagulated epistaxis patients had supratherapeutic levels 6
Clinical Assessment Beyond Labs
Severity stratification:
- Determine if this is minor, clinically relevant non-major, or major bleeding (requiring transfusion, hospitalization, or involving critical sites) 1
- Minor epistaxis may still warrant drug discontinuation—studies show 33% of patients with minor epistaxis permanently stop anticoagulation 7
Timing of last dose:
- Critical for determining drug effect and clearance timeline
- Apixaban is dosed twice daily; knowing when the last dose was taken guides management 1
Concurrent medications:
- NSAIDs, antiplatelet agents, SSRIs/SNRIs all increase bleeding risk 2
- Drug interactions affecting CYP3A4 or P-glycoprotein can alter apixaban levels
Management Algorithm Based on Findings
If bleeding is minor and labs are reassuring:
- Local measures (pressure, nasal packing if needed)
- Consider holding next dose(s) based on CrCl and bleeding severity
- Resume when hemostasis achieved
If bleeding is major or life-threatening:
- Andexanet alfa is the specific reversal agent for apixaban (dose depends on timing and dose of last apixaban intake) 1
- If andexanet unavailable: 4-factor PCC or aPCC 1
Common Pitfall
Do not assume normal PT/aPTT means no drug effect—these tests are not sensitive for apixaban levels 3, 4. The absence of prolonged coagulation studies does not exclude clinically significant anticoagulation from apixaban.